Kraig Biocraft Laboratories Reports No Revenue and Increased Losses in Latest Quarter

Kraig Biocraft Laboratories, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no revenue for both the three and nine months ended September 30, 2025, consistent with the same periods in the previous year. Operating expenses surged to $1.43 million for the third quarter, a 238% increase from $423,797 in the same quarter of 2024. For the nine-month period, total operating expenses reached $2.65 million, up 12.4% from $2.36 million in the prior year. The net loss for the third quarter was $1.51 million, compared to a loss of $433,200 in the same quarter of 2024, while the nine-month net loss increased to $2.84 million from $2.55 million year-over-year.

The company's balance sheet reflects a notable increase in total assets, which rose to $2.36 million as of September 30, 2025, compared to $1.51 million at the end of 2024. This increase was primarily driven by a rise in cash and cash equivalents, which grew to $1.57 million from $673,264, and inventory, which increased to $29,067 from $6,884. However, total liabilities also increased to $10.31 million from $9.65 million, resulting in a working capital deficit of $8.54 million, slightly improved from $8.87 million at the end of 2024.

Strategically, Kraig Biocraft Laboratories has focused on expanding its operations, particularly in Vietnam, where it has been working on enhancing sericulture through partnerships with local organizations. The company has also been active in issuing common stock to raise capital, with $1.93 million raised from the sale of 24.3 million shares during the nine months ended September 30, 2025. This capital is intended to support ongoing research and development efforts, as well as operational expenses.

Operationally, the company has not reported any significant customer growth or product adoption metrics, and it continues to face challenges in achieving commercial scale production of its recombinant spider silk fibers. The management has acknowledged the need for additional funding to sustain operations and has outlined plans to pursue further capital through equity or debt financing. The company’s ability to continue as a going concern remains uncertain, as it has incurred substantial losses and has a significant accumulated deficit of $55.92 million as of September 30, 2025.

Looking ahead, Kraig Biocraft Laboratories aims to accelerate its production capabilities and expand its research initiatives. The company plans to explore potential acquisitions to broaden its financial base and enhance commercialization efforts. However, the management has cautioned that the success of these initiatives is contingent upon securing adequate financing and achieving sustainable revenue streams. The outlook remains cautious, with substantial doubt about the company's ability to continue operations without additional capital.